Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Net Cash Flow (2016 - 2025)

Apyx Medical (APYX) has disclosed Net Cash Flow for 15 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 86.7% year-over-year to $6.7 million, compared with a TTM value of $465000.0 through Dec 2025, up 103.87%, and an annual FY2025 reading of $465000.0, up 103.87% over the prior year.
  • Net Cash Flow was $6.7 million for Q4 2025 at Apyx Medical, up from -$4.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $21.5 million in Q4 2023 and bottomed at -$6.4 million in Q1 2024.
  • Average Net Cash Flow over 5 years is -$506450.0, with a median of -$3.1 million recorded in 2021.
  • The sharpest move saw Net Cash Flow tumbled 2882.17% in 2022, then soared 560.04% in 2023.
  • Year by year, Net Cash Flow stood at -$157000.0 in 2021, then crashed by 2882.17% to -$4.7 million in 2022, then skyrocketed by 560.04% to $21.5 million in 2023, then tumbled by 83.39% to $3.6 million in 2024, then surged by 86.7% to $6.7 million in 2025.
  • Business Quant data shows Net Cash Flow for APYX at $6.7 million in Q4 2025, -$4.0 million in Q3 2025, and -$1.5 million in Q2 2025.